Is Enovix an Underrated Small Cap?
Enovix (NASDAQ:ENVX) is one of several small, innovative companies hoping…
Sell
34
SLRX Quote, Financials, Valuation and Earnings
Last price:
$0.84
Seasonality move
:
-13.99%
Day range:
$0.76 - $0.80
52-week range:
$0.45 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.09x
Volume:
23K
Avg. volume:
183.3K
1-year change:
-81.01%
Market cap:
$1.6M
Revenue:
--
EPS (TTM):
-$7.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLRX
Salarius Pharmaceuticals
|
-- | -$53.60 | -- | -928.79% | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.28 | -100% | -5.26% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$1.56 | -- | -8.25% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLRX
Salarius Pharmaceuticals
|
$0.77 | -- | $1.6M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.48 | $5.00 | $46.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.56 | $0.85 | $3.3M | -- | $0.00 | 0% | 0.15x |
|
NNVC
Nanoviricides
|
$1.32 | -- | $20.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.17 | $1.00 | $3.6M | -- | $0.00 | 0% | 1.05x |
|
TOVX
Theriva Biologics
|
$0.53 | $7.00 | $1.5M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLRX
Salarius Pharmaceuticals
|
-- | 0.087 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.541 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLRX
Salarius Pharmaceuticals
|
-- | -$1.5M | -- | -- | -- | -$742.5K |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$12.6M | -95.08% | -95.08% | -12769.14% | -$12M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
NNVC
Nanoviricides
|
-- | -$2.1M | -- | -- | -- | -$2.2M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Salarius Pharmaceuticals vs. Competitors
-
Which has Higher Returns SLRX or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to Salarius Pharmaceuticals's net margin of -11511.11%. Salarius Pharmaceuticals's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital SLRXSalarius Pharmaceuticals-- -$1.02 -- ATNMActinium Pharmaceuticals-- -$0.37 $36.4M -
What do Analysts Say About SLRX or ATNM?
Salarius Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3272.24%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 237.84%. Given that Salarius Pharmaceuticals has higher upside potential than Actinium Pharmaceuticals, analysts believe Salarius Pharmaceuticals is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SLRXSalarius Pharmaceuticals0 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is SLRX or ATNM More Risky?
Salarius Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.09% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.
-
Which is a Better Dividend Stock SLRX or ATNM?
Salarius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLRX or ATNM?
Salarius Pharmaceuticals quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. Salarius Pharmaceuticals's net income of -$1.5M is higher than Actinium Pharmaceuticals's net income of -$11.6M. Notably, Salarius Pharmaceuticals's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLRXSalarius Pharmaceuticals-- -- -- -$1.5M ATNMActinium Pharmaceuticals-- -- $81K -$11.6M
-
Which has Higher Returns SLRX or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Salarius Pharmaceuticals's net margin of -49.65%. Salarius Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital SLRXSalarius Pharmaceuticals-- -$1.02 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About SLRX or NBY?
Salarius Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3272.24%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Salarius Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Salarius Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SLRXSalarius Pharmaceuticals0 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is SLRX or NBY More Risky?
Salarius Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.09% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock SLRX or NBY?
Salarius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLRX or NBY?
Salarius Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Salarius Pharmaceuticals's net income of -$1.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Salarius Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLRXSalarius Pharmaceuticals-- -- -- -$1.5M NBYNovaBay Pharmaceuticals0.15x -- $2.4M -$1.2M
-
Which has Higher Returns SLRX or NNVC?
Nanoviricides has a net margin of -- compared to Salarius Pharmaceuticals's net margin of --. Salarius Pharmaceuticals's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLRXSalarius Pharmaceuticals-- -$1.02 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About SLRX or NNVC?
Salarius Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3272.24%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 392.42%. Given that Salarius Pharmaceuticals has higher upside potential than Nanoviricides, analysts believe Salarius Pharmaceuticals is more attractive than Nanoviricides.
Company Buy Ratings Hold Ratings Sell Ratings SLRXSalarius Pharmaceuticals0 0 0 NNVCNanoviricides0 0 0 -
Is SLRX or NNVC More Risky?
Salarius Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.09% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock SLRX or NNVC?
Salarius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLRX or NNVC?
Salarius Pharmaceuticals quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Salarius Pharmaceuticals's net income of -$1.5M is higher than Nanoviricides's net income of -$2M. Notably, Salarius Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLRXSalarius Pharmaceuticals-- -- -- -$1.5M NNVCNanoviricides-- -- -- -$2M
-
Which has Higher Returns SLRX or OGEN?
Oragenics has a net margin of -- compared to Salarius Pharmaceuticals's net margin of --. Salarius Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLRXSalarius Pharmaceuticals-- -$1.02 -- OGENOragenics-- -$0.27 -- -
What do Analysts Say About SLRX or OGEN?
Salarius Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3272.24%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 493.12%. Given that Salarius Pharmaceuticals has higher upside potential than Oragenics, analysts believe Salarius Pharmaceuticals is more attractive than Oragenics.
Company Buy Ratings Hold Ratings Sell Ratings SLRXSalarius Pharmaceuticals0 0 0 OGENOragenics0 1 0 -
Is SLRX or OGEN More Risky?
Salarius Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.09% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock SLRX or OGEN?
Salarius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLRX or OGEN?
Salarius Pharmaceuticals quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Salarius Pharmaceuticals's net income of -$1.5M is higher than Oragenics's net income of -$3.3M. Notably, Salarius Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals is -- versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLRXSalarius Pharmaceuticals-- -- -- -$1.5M OGENOragenics1.05x -- -- -$3.3M
-
Which has Higher Returns SLRX or TOVX?
Theriva Biologics has a net margin of -- compared to Salarius Pharmaceuticals's net margin of --. Salarius Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SLRXSalarius Pharmaceuticals-- -$1.02 -- TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About SLRX or TOVX?
Salarius Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 3272.24%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1032.29%. Given that Salarius Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Salarius Pharmaceuticals is more attractive than Theriva Biologics.
Company Buy Ratings Hold Ratings Sell Ratings SLRXSalarius Pharmaceuticals0 0 0 TOVXTheriva Biologics1 1 0 -
Is SLRX or TOVX More Risky?
Salarius Pharmaceuticals has a beta of 0.419, which suggesting that the stock is 58.09% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock SLRX or TOVX?
Salarius Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Salarius Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLRX or TOVX?
Salarius Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Salarius Pharmaceuticals's net income of -$1.5M is higher than Theriva Biologics's net income of -$4.4M. Notably, Salarius Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Salarius Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLRXSalarius Pharmaceuticals-- -- -- -$1.5M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Are We Heading Toward a Recession?
Fears of a recession in 2025 grew at the end…
3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 12
Regencell Bioscience Holdings [RGC] is up 41.59% over the past day.
Buy
97
NGVC alert for May 12
Natural Grocers by Vitamin Cottage [NGVC] is down 7.43% over the past day.
Sell
38
ONTO alert for May 12
Onto Innovation [ONTO] is up 4.73% over the past day.
